Preventing secondary hip fractures in postmenopausal women
Official title: Randomized Controlled Study of a Local Osteo-Enhancement Procedure (LOEP) to Prevent Secondary Hip Fractures in Osteoporotic Women Undergoing Treatment of Index Hip Fractures
Run by AgNovos Healthcare, LLC · NCT04796350 · Data updated 2026-11-12
This study is testing if a new treatment can help prevent additional hip fractures in postmenopausal women who have already broken a hip and are having surgery to fix it.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 65 Years to 91 Years |
| Sex | Women only |
| Enrollment | 2400 (estimated) |
| Sponsor | AgNovos Healthcare, LLC Industry-sponsored |
| Locations | 66 sites (Innsbruck and 65 other locations) |
| Status | Recruiting |
| Started | April 24, 2021 |
| Main results expected | April 1, 2027 |
| Study ends | April 1, 2029 |
| Registry record updated | May 13, 2026 |
| Trial ID | NCT04796350 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are postmenopausal women aged 65 and older with a low-energy index hip fracture and additional risk factors for secondary fractures.
✕Probably not a fit
Patients who do not have a history of fragility fractures or those who are not postmenopausal may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial evaluates the effectiveness of AGN1 LOEP treatment in preventing secondary hip fractures in postmenopausal women who have experienced an index hip fracture and are undergoing surgical repair. Up to 2400 subjects will be randomly assigned to either receive the AGN1 LOEP treatment on the unfractured hip or serve as a control group without the treatment. Participants will be monitored for a minimum of 5 years through scheduled visits to assess the incidence of secondary fractures. The study aims to provide insights into the long-term benefits of AGN1 LOEP in this high-risk population.
Why it matters
Potential benefit: If successful, this treatment could significantly reduce the risk of secondary hip fractures in vulnerable postmenopausal women.
How similar studies have gone: Other studies have shown promise in similar approaches to fracture prevention, but the specific use of AGN1 LOEP is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
1. Subject is a postmenopausal female at least 1-year post menses and at least 65 years of age and less than 92 years of age.
2. Subject presents with a low-energy index fragility hip fracture in one hip and will undergo surgical repair of the fractured hip.
3. Subject has at least one of the following additional risk factors for a secondary hip fracture (as determined by subject or legally authorized representative (LAR) interview or medical record review):
* Documented falls assessment indicating subject is at moderate or high risk of falls
* Falls history (2 or more falls in the previous 12 months)
* History of vertigo, dizziness, or postural hypotension
* Documented T-score \< -2.5 at the hip
* Taking more than 3 daily prescription medications
* Visual impairment as confirmed by one of the following:
* Subject reports difficulty seeing
* Lack of depth perception or vision loss in one eye
* Macular degeneration
* Cataracts
* Prior non-hip fragility fracture
* Cognitive frailty as assessed by SPMSQ (mild cognitive impairment determined by SPMSQ ≤ to 4) or delirium
* Parkinson's disease stage 3 or 4
* 10-year hip fracture probability \>15% using the FRAX® Fracture Risk Assessment Tool of the clinical site country
4. Subject is expected to be ambulatory after the hip fracture repair procedure. "Ambulatory" is defined as a patient's ability to ambulate beyond simple transfers with or without assistive devices.
5. Informed consent is provided by the subject or the subject's LAR. Use of an LAR to obtain patient consent requires that the patient must understand and be able to participate in post operative restrictions and requirements.
6. The subject's willingness, ability, and commitment to participate in screening, treatment, and all follow-up evaluations for the full duration of the study has been documented.
Exclusion Criteria:
1. Criterion omitted
2. Criterion omitted
3. Subject is currently enrolled in another interventional clinical study affecting the target hip.
4. Subject has a history of hip surgery or previous hip fracture on the target unfractured hip contralateral to the index hip fracture.
5. Subject has new fractures in addition to the index hip fracture at admission that, in the opinion of the investigator, would further compromise patient mobility, rehabilitation, or recovery.
6. Subject has an infection at the LOEP intended treatment site or has non-intact skin or acute traumatic injuries with open wounds close to the area of intended LOEP treatment.
7. Subject has a progressive increase in undiagnosed pain in the target hip contralateral to the index fractured hip over the previous 3 months that in the opinion of the Investigator may suggest underlying bone or joint pathology on the unfractured side.
8. Subject has radiological evidence of gross bony or joint pathology of the hip, including signs predictive of atypical femoral fractures (e.g. cortical beaking), or has been diagnosed and/or treated for atypical femoral fractures.
9. Criterion omitted
10. Subject has a history of metabolic bone disease other than osteoporosis (e.g., Paget's disease, renal osteodystrophy, or osteomalacia).
11. Criterion omitted
12. Subject has active cancer
13. Criterion omitted
14. Criterion omitted
15. Criterion omitted
16. Criterion omitted
17. Criterion omitted
18. Subject has end stage renal insufficiency defined as an estimated glomerular filtration rate (eGFR) \< 15 mL/min.
19. Criterion omitted
20. Criterion omitted
21. Subject has moderate or severe cognitive impairment as assessed by an SPMSQ of 5 or higher.
22. Subject has known allergies to calcium-based bone void fillers.
23. In the judgement of the Investigator, the subject is not a good study candidate (e.g., poor mental health, or active drug or alcohol abuse issues), and or subject would not be a good candidate to undergo an ELECTIVE orthopedic surgical procedure such as a total hip arthroplasty in her current medical, physiological condition.
24. Subject fails pre-operative or intraoperative eligibility criteria as specified in section 7.4.2. of the clinical investigation plan.
Where it's running
-
Innsbruck Hospital
Innsbruck, Austria Recruiting -
Ziekenhuis Oost-Limburg
Genk, Belgium Recruiting -
Ghent University Hospital
Ghent, Belgium Recruiting -
UZ Leuven
Leuven, Belgium Recruiting -
Vitaz Sint-Niklaas
Sint-Niklaas, Belgium Recruiting -
QEII Health Sciences Centre
Halifax, Nova Scotia, Canada Recruiting
Show 44 more locations
-
Sunnybrook Health Sciences Centre
North York, Ontario, Canada Recruiting -
Aarhus University Hospital
Aarhus, Denmark Recruiting -
CHU de Nice
Nice, Provence-Alpes-Côte d'Azur Region, France Recruiting -
CHU Amiens
Amiens, France Recruiting -
CHU Grenoble-Alpes
Grenoble, France Recruiting -
Charite University Hosptial
Berlin, Germany Recruiting -
Universitatsklinikum Schleswig-Holstein
Kiel, Germany Recruiting -
Klinikum der Universität München
München, Germany Recruiting -
Azienda Ospedaliero Universitaria Careggi
Florence, Italy Recruiting -
ASST Gaetano Pini CTO
Milan, Italy Recruiting -
Policlinico Tor Vergata
Rome, Italy Recruiting -
CTO Torino
Torino, Italy Recruiting -
Akita City Hospital
Akita, Akita, Japan Recruiting -
Southern Tohoku General Hospital
Kōriyama, Fukushima, Japan Recruiting -
Hyogo Prefectural Nishinomiya Hospital
Nishinomiya, Hyōgo, Japan Recruiting -
Kagawa Rosai Hospital
Marugame, Kagawa-ken, Japan Recruiting -
Kanto Rosai Hospital
Kawasaki, Kanagawa, Japan Recruiting -
Okayama Medical Center
Okayama, Okayama-ken, Japan Recruiting -
St. Mary's Hospital
Fukuoka, Japan Recruiting -
Iwata City Hospital
Iwata, Japan Recruiting -
Shin-Yurigaoka General Hospital
Kawasaki-shi, Japan Recruiting -
National Hospital Organization Kumamoto Medical Center
Kumamoto, Japan Recruiting -
Saga-Ken Medical Centre Koseikan
Saga, Japan Recruiting -
Japanese Red Cross Shizuoka Hospital
Shizuoka, Japan Recruiting -
Deventer Hospital
Deventer, Netherlands Recruiting -
Maastricht UMC
Maastricht, Netherlands Recruiting -
Vall d'Hebron University Hospital
Barcelona, Barcelona, Spain Recruiting -
Valladolid University Clinic Hospital
Valladolid, Valladolid, Spain Recruiting -
Clinic de Barcelona
Barcelona, Spain Recruiting -
Hospital Universitario de Basurto
Bilbao, Spain Recruiting -
Galdakao-Usansolo Hospital
Galdakao, Spain Recruiting -
Hospital Neuro-Traumatológico de Jaén
Jaén, Spain Recruiting -
Hospital Clínico San Carlos
Madrid, Spain Recruiting -
Hospital Universitario 12 de Octubre
Madrid, Spain Recruiting -
Hospital Universitario Infanta Leonor
Madrid, Spain Recruiting -
Hospital St Joan de Deu
Manresa, Spain Recruiting -
Mutua de Terrassa University Hospital
Terrassa, Spain Recruiting -
Leicester Royal Infirmary
Leicester, England, United Kingdom Recruiting -
Royal Infirmary of Edinburgh
Edinburgh, Scotland, United Kingdom Recruiting -
Queen Elizabeth Glasgow
Glasgow, United Kingdom Recruiting -
Wythenshawe Hospital Manchester
Manchester, United Kingdom Recruiting -
Nottingham University Hospitals, Queen's Medical Center
Nottingham, United Kingdom Recruiting -
Health Sciences Centre - Eastern Health
St. John's, Newfoundland and Labrador, Canada Withdrawn -
CHU Lyon
Lyon, France Withdrawn
+16 more sites. See ClinicalTrials.gov for the full list.
Study contacts
- Study coordinator: Charles Raymond
- Email: restore@agnovos.com
- Phone: 240-753-6421
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Improving outcomes for patients with fragility fractures
This study is testing if a new support program for older adults with recent bone fractures can help them recover better than standard care that just provides education.
-
Improving collaboration in osteoporosis treatment after hip fractures
This study is testing if better teamwork between doctors can help older patients who have had a hip fracture get the right osteoporosis treatment to prevent more fractures.
-
Surgeon-driven bone health referral for patients having lower limb joint replacement
This study is testing if sending patients with osteoporosis to a bone health specialist before getting lower limb joint replacement surgery can help reduce fractures and complications compared to regular care.
-
Analyzing metabolic profiles of blood stem cells in older adults with clonal hematopoiesis
This study is trying to see how aging affects blood stem cells in older adults with certain genetic changes, by looking at blood and bone marrow samples taken during hip surgery.
-
Analyzing bone damage in patients with osteoporosis and fragility fractures
This study is testing how tiny changes in bones affect fracture risk in people with osteoporosis and fragility fractures who are having hip replacement surgery.
-
Second hip fracture risk in Chinese patients with osteoporotic hip fractures
This project will see if CT-based measurements of bone and muscle can predict second hip fractures in older adults who have already had an osteoporotic hip fracture.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.